SuperworthActinium Pharmaceuticals ATNM
- Market cap
- $47.8M
- PE
- 4.2×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- 1.2×
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Actinium Pharmaceuticals trades at 4.2× trailing earnings.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $90K | $0 | n/a | $35M | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $11.6M+72% | $8.1M+11% | $6.6M−16% | $8.8M−20% | $9.8M−16% | $4.8M−41% | $7.7M+16% | $4.9M−45% | $4.2M−57% | $4.3M−11% | $4.2M−45% | $5.4M+10% |
| SG&A | $2.7M−11% | $2.3M−42% | $3M−21% | $3.6M−21% | $2.8M+4% | $2.7M+17% | $8.9M+202% | $2.6M−27% | $1.5M−46% | $2.1M−21% | $1.7M−81% | $2.1M−22% |
| −$14.4M+47% | −$10.3M−8% | −$9.6M−17% | −$12.4M−21% | −$12.6M−12% | −$7.5M−27% | −$16.6M+73% | −$7.5M−40% | −$5.7M−55% | −$6.4M−15% | −$5.9M−65% | $27.6M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$13.3M+40% | −$9.3M−12% | −$8.7M−21% | −$11.4M−25% | −$11.6M−13% | −$6.7M−29% | −$15.9M+84% | −$6.9M−39% | −$5.1M−56% | −$5.9M−11% | −$5.5M−65% | $27.9M |
| −$0.49+29% | −$0.34−19% | −$0.31−28% | −$0.38−35% | −$0.37−25% | −$0.21−38% | −$0.51+65% | −$0.22−42% | −$0.16−57% | −$0.19−10% | −$0.18−65% | $0.89 | |
| 27.1M+8% | 27.4M+8% | 27.9M+9% | 30.1M+15% | 31.1M+15% | 31.2M+14% | 31.2M+12% | 31.2M+4% | 31.2M+0% | 31.2M+0% | 31.2M+0% | 31.4M+1% |
EPS, diluted: 23 periods, Q3 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q3 FY11: a loss quarter: its basic count, share-days: the 9-month average less the 6-month, weighted by days. 14 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Actinium Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| Peer median | $143.6M | 13.3× | 20.1× | 0.9× | −9% | 3.3% |
More on Actinium Pharmaceuticals
Each number over time
Where it ranks
- #2of 202Healthcare stocks with the lowest EV/EBIT
- #2of 168Healthcare stocks with the lowest PE ratio
- #1of 48Large drugmakers with the lowest EV/EBIT
- #2of 41Large drugmakers with the lowest PE ratio
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .